Panel tells FDA risks of Medtronic heart device outweigh benefits
The news is a blow for Medtronic and investors, who expected big things from an experimental device that uses extreme heat to regulate heartbeat. Medtronic bought the company that developed the device for $225 million in 2009. The panel's recommendation isn't the final say, but the FDA will take it under consideration.
The news is a blow for Medtronic and investors, who expected big things from an experimental device that uses extreme heat to regulate heartbeat. Medtronic bought the company that developed the device for $225 million in 2009. The panel's recommendation isn't the final say, but the FDA will take it under consideration.
